FY2024 EPS Estimates for Teleflex Incorporated Lifted by Zacks Research (NYSE:TFX)

Teleflex Incorporated (NYSE:TFX) – Analysts at Zacks Research increased their FY2024 earnings per share estimates for shares of Teleflex in a report released on Thursday, May 9th. Zacks Research analyst R. Department now anticipates that the medical technology company will earn $13.70 per share for the year, up from their previous estimate of $13.64. The consensus estimate for Teleflex’s current full-year earnings is $13.75 per share. Zacks Research also issued estimates for Teleflex’s Q2 2025 earnings at $3.74 EPS and Q4 2025 earnings at $4.07 EPS.

Several other brokerages have also weighed in on TFX. Royal Bank of Canada dropped their target price on Teleflex from $272.00 to $265.00 and set an “outperform” rating on the stock in a research report on Friday, February 23rd. StockNews.com lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Truist Financial dropped their target price on Teleflex from $240.00 to $219.00 and set a “hold” rating on the stock in a research report on Friday, May 3rd. JMP Securities reaffirmed a “market outperform” rating and issued a $285.00 target price on shares of Teleflex in a research report on Friday, February 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a report on Friday, May 3rd. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Teleflex currently has a consensus rating of “Moderate Buy” and an average target price of $261.75.

Teleflex Price Performance

Shares of NYSE TFX opened at $203.93 on Monday. Teleflex has a 1-year low of $177.63 and a 1-year high of $262.97. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.51 and a quick ratio of 1.41. The business’s fifty day moving average price is $215.01 and its two-hundred day moving average price is $226.81. The firm has a market capitalization of $9.61 billion, a PE ratio of 32.73, a P/E/G ratio of 1.98 and a beta of 1.13.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, May 2nd. The medical technology company reported $3.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.14. The business had revenue of $737.80 million for the quarter, compared to analyst estimates of $726.85 million. Teleflex had a return on equity of 14.78% and a net margin of 9.82%. The business’s revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company posted $3.09 EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Rafferty Asset Management LLC boosted its position in shares of Teleflex by 6.8% in the 3rd quarter. Rafferty Asset Management LLC now owns 4,910 shares of the medical technology company’s stock valued at $964,000 after purchasing an additional 314 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Teleflex by 243.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 22,722 shares of the medical technology company’s stock valued at $5,666,000 after purchasing an additional 16,110 shares during the period. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Teleflex by 22.3% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 1,366 shares of the medical technology company’s stock valued at $341,000 after purchasing an additional 249 shares during the period. Royal London Asset Management Ltd. boosted its position in shares of Teleflex by 4.3% in the 3rd quarter. Royal London Asset Management Ltd. now owns 17,753 shares of the medical technology company’s stock valued at $3,487,000 after purchasing an additional 737 shares during the period. Finally, New York Life Investment Management LLC boosted its position in shares of Teleflex by 63.6% in the 4th quarter. New York Life Investment Management LLC now owns 12,139 shares of the medical technology company’s stock valued at $3,027,000 after purchasing an additional 4,717 shares during the period. Institutional investors own 95.62% of the company’s stock.

Insider Activity at Teleflex

In related news, VP Cameron P. Hicks sold 7,401 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the completion of the transaction, the vice president now owns 10,050 shares of the company’s stock, valued at $2,261,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.43% of the company’s stock.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Wednesday, May 15th will be paid a dividend of $0.34 per share. The ex-dividend date is Tuesday, May 14th. This represents a $1.36 annualized dividend and a yield of 0.67%. Teleflex’s dividend payout ratio is currently 21.83%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.